Sussidi assegnati


The immune inhibitory receptor VISTA as regulator of stemness in acute myeloid leukemia

University of Bern

Department of BioMedical Research (MEM) E808

Murtenstrasse 35

3008 Bern

Prof. PhD Carsten Riether

CHF 200’00.00


Targeting dysregulated inflammasome activation in Myeloid Malignancies

Universitätsklinik für Hämatologie Inselspital/Universitätsspital

Department for BioMedical Research, University of Bern

Murtenstrasse 40,

3000 Bern

PD. Dr. Ramanjaneyulu Allam

CHF 197'463.00


Genome-Wide CRISPR-Knockout Screen for Identification of Immunomodulatory Genes in Glioblastoma

Department of Neurology, University Hospital Zurich

Frauenklinikstrasse 26,

8091 Zürich

Prof. Dr. med. Michael Weller

CHF 175’000.00


Studying neutrophils as mediators of synthetic lethality, sensitizing breast cancer to immunotherapy

IOR Institute of Oncology Research

Via Francesco Chiesa 5

6500 Bellinzona

Prof. PhD Arianna Calcinotto

CHF 250’000.00


Role of LCMT1 in T Cell Exhaustion and Cancer Immunotherapy

Department for Biomedicine ZLF

Universitätsspital Basel

Hebelstrasse 20

4031 Basel

Dr. med. Dominic Schmid, MD-PhD student in Experimental Biomedicine | 09/2019 - present

CHF 245’380.00



Loss of cell-cycle checkpoints in order to maximize low-dose radiation-induced inflammatory responses and sensitize ovarian cancer to immune checkpoint blockade therapy

Chemin de la Fauvette 61, 1012 Lausanne

MD, PhD Fernanda Herrera 

CHF 190'000.00


Precision Oncology Targeting of Folic Acid Metabolism in Pediatric Osteosarcoma

University Children's Hospital Zürich, Steinwiesstrasse 75, 8032 Zürich

Dr. med. Univ. et Dr. phil Raphael Johannes Jonathan Morscher

CHF 241’738.00


Mitochondrial reprogramming to restore age-driven dysfunction in T cell and boost

CAR-T cell therapy

Department of oncology UNIL CHUV, Ludwig Institute for Cancer Research Lausanne, Biopole 3 Chemin des Boveresses 155, 1066 Epalinges

PhD Nicola Vannini Group Leader

CHF 135’808.00


Characterization and optimization of small molecules able to restore PTEN physiological levels and/or activity in prostate cancer

Head Computational Structural Biology, Institute for Research in Biomedicine, Via

Vincenzo Vela 6, 6500 Bellinzona

Dr. Andrea Cavalli, PhD

CHF 160'600.00


TAXIS — Tailored Axillary Surgery

Brustchirurgie, Universitätsspital Basel, Spitalstrasse 21, 4031 Basel

Prof. Dr. Walter Weber

CHF 126'870.00


Transcriptional regulation of T cell lymphoma development

Institute for Research in Biomedicine, Via Vincenzo Vela 6, 6500 Bellinzona

PhD Silvia Monticelli

CHF 153'000.00


Advancing cancer immunotherapy with non-viral engineering of multifunctional CAR T cells

Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Ramistrasse 100, 8091 Zurich

PhD Assisant Professor Chiara Francesca Magnani

CHF 210'000.00


Mechanisms of cancer resistance to CAR-T cell therapy

Istituto di Ricerca in Biomedicina, Via Vincenzo Vela 6, 6500 Bellinzona

Prof. Dr. Roger Geiger

CHF 190'000.00


Use of lymphoma ex-vivo biopsies as a platform to anticipate individual response to therapies

Swiss Institute for Experimental Cancer Research EPFL, 1015 Lausanne

PhD, Associate Professor Elisa Oricchio

CHF 177’000.00


Differential role of IL-33 in colorectal cancer development

Institute of Pathology, University of Bern, Murtenstrasse 31, 3008 Bern

PD (Dr. Sc. Nat. ETHZ), Prof. Philippe Krebs

CHF 170’000.00


MET as a target for combined modality treatment of glioblastoma

Chairman University Hospital Zurich, Department of Neurology

Frauenklinikstrasse 26,

8091 Zurigo (Svizzera)

Prof. Dr. Michael Weller

CHF 250'000.00


Impact of the tyrosine kinase inihibitor disatinib on lymphoid tissue microenvironment and tumor cell niche

Dept. OMI, University of Fribourg

Ch. du Musee 5,

1700 Friborgo (Svizzera)

Prof. Jens V. Stein

CHF 187'289.00


Identifying the mode of action of the anti-tumor immune response induced by selected Clostridiales bacteria in colorectal cancer patients

Leiter Forschung, Leiter Translationales Mikrobiom Forschungszentrum

Universitatsspital Zurich, Klinik fur Gastroenterologie and Hepatologie

Ramistrasse 100,

8091 Zurigo (Svizzera)

Prof. Dr. med. Michael Scharl

CHF 168'291.00


PREDICT — Peptide Radiotracers Enabling high-contrast PD-1 targeted Diagnostic Imaging of antigen-experienced T-cells for improved prediction of response to Immune Checkpoint targeted Therapies

Translational Radiopharmaceutical Sciences, Department of Nuclear Medicine and Molecular Imaging, CHUV, Department of Oncology,

UNIL, Centre Hospitalier Universitaire Vaudois (CHUV)

Agora, B25A/03/094

Rue du Bugnon 25A,

1011 Lausanna (Svizzera)

Prof. Dr. Margret Schottelius

CHF 216'000.00


Immunotherapy of breast carcinoma through combination of PLGA-microsphere based vaccination with immune checkpoint blockade

Biotechnology Institute Thurgau Unterseestrasse 47

8280 Kreuzlingen (Svizzera)

Prof.Dr. Marcus Groettrup

CHF 140'000.00


“Helping the Killers”: innovative cancer immunotherapy harnessing “quasi-universal” tumor-specific CD4 T cells

Targeting of Cytokine secreting lymphocyte (TCSL) group

Department of Oncology UNIL-CHUV and Ludwig Institute for Cancer Research Biopole III, Chemin des Boveresses 155

1066 Epalinges (Svizzera)

MD, Ph.D. Camilla Jandus-Marone SNSF Assistant Professor,

CHF 150’000.00


Analysis of the tumor immune signature and effect of immunotherapy in a mouse model of small cell lung cancer.

Ecole Polytechnique Federale de Lausanne, Station 19, 1015 Lausanne (Svizzera)

Etienne Meylan, PhD

CHF 70'000.00


Extracellular ATP as target in tumor environment to improve adaptive immunity.

Istituto di Ricerca in Biomedicina (IRB), Via Vela 6, 6500 Bellinzona (Svizzera)

Fabio Grassi, MD, PhD

CHF 162'000.00


Examination of the tumor environment to boost immunotherapy in pancreatic cancer.

Experimental Pathology, University of Bern, 3000 Bern (Svizzera)

Mirjam Schenk, PhD

CHF 143'000.00


Targeting chemoresistance and tumor microenvironment in colon cancer.

Division of Experimental Pathology, CHUV 1015 Lausanne (Svizzera)

Tatiana Petrova, PhD

CHF 87'000.00


A proof-of-concept, prospective, observational study to investigate the value of Liquid Biopsies to predict tumor response after neoadjuvant chemo-radiotherapy in patients with locally advanced Rectal Cancer: the LiBReCa study.

Istituto cantonale di patologia, 6600 Locarno (Svizzera)

Prof. Dr. med. Dimitri Christoforidis

CHF 158’000.00


The ethical communication of medical diagnosis and prognosis: a certificate of advanced studies (CAS) through Medical Humanities.

Fondazione Sasso Corbaro, 6500 Bellinzona (Svizzera)

Prof. Dr. med. Roberto Malacrida

CHF 10’000.00


Uncovering the T cell-intrinsic role of NLRC5 in antitumoral responses.

Department of Biochemistry, University of Lausanne, Chemin des Boveresses 155, 1066 Epalinges (Svizzera)

Greta Guarda, PhD,

CHF 153’140.00


TCR activation is compromised in CD8 T cells transduced with a Chimeric Antigen Receptor (CAR). Implications for CAR-T cell mediated immunotherapy.

Departement of Fundamental Oncology and Ludwig Center for Cancer

Research- Biopole 3, Ch.des Boveresses 155, 1066 Epalinges


Alena Donda PhD

CHF 65’000.00


Intravital study of the traffcking of B lymphoma cells in the lymphatic compartment.

IRB, Institute for Research in Biomedicine, Via Vela 6, 6500 Bellinzona (Svizzera)

Fernandez Gonzales Santiago PhD, PhD.

CHF 200’000.00


Understanding and targeting chemoresistance in colorectal cancer.

University of Lausanne and CHUV, Ch. Des Boveresses 155, 1066 Epalinges (Svizzera)

Tatiana Petrova PhD.

CHF 70’000.00


Modulation of colorectal cancer immune contexture by gut microbiota.

Universitätsspital Basel, Zentrum für Lehre und Forschung (ZLF),

Hebelstrasse 20, 4031 Basel (Svizzera)

Giandomenica Iezzi, PD Dr. med.

CHF 120'000.00


Dissecting the association of the human palatine tonsil microbiome and HPV-driven oropharyngeal squamous cell carcinoma

Institut für Immunbiologie 

Rorschacher Strasse 95, Kantonspital St.Gallen (Svizzera)

Prof. Dr. Ludewig Burkhard

CHF 144’000.00


Novel Active Combinations Containing Bromodomain (BRD) and Extra-terminal (BET) Inhibitors for Patients with Germinal Center B-cell Type

Diffuse large B-cell lymphoma

Institute of Oncology Research, Via Vela 6, 6500 Bellinzona (Svizzera)

Eugenio Gaudio PhD

CHF 160’000.00


Role of BCL2 genetic heteroclonality in the pathogenesis of B-cell lymphomas with BCL2 rearrangement

Istituto Cantonale di Patologia, Via in Selva 24, 6600 Locarno (Svizzera)

Prof. Dr. Med. Luca Mazzucchelli

CHF 170’000.00


Oncogenic aversion: A concept towards new therapeutic avenues in prostate cancer

Institute of Oncology Research, Via Vela 6, 6500 Bellinzona (Svizzera)

Prof. Dr. med. Jean-Philippe Theurillat

CHF 170’000.00


Role of Notch signaling and therapeutic potential of exosomes in

cardiomyopathy induced by doxorubicin & trastuzumab cancer treatment

Cardiocentro Ticino, Via Tesserete 48, 6900 Lugano (Svizzera)

Prof. Dr. med. Giuseppe Vassalli

CHF 120'000.00


Dissecting critical cellular and molecular mechanisms of acute erythroleukemia

University of Basel, Department of Biomedicine, ZLF, Childhood leukemia

group, Hebelstrasse 20, 4031 Basel, (Svizzera)

Prof. Dr. med. Jürg Schwaller

CHF 120'000.00


Role of IL-33/ST2 signaling in intestinal tumorigenesis

Institute of Pathology, P.O. Box 62, Murtenstrasse 31, 3010 (Svizzera)

Philippe Krebs, PhD

CHF 120’000.00 


Co-targeting angiogenesis and immunosuppression to improve cancer therapy

ISREC-EPFL SV, Batiment SV, Station 19-Room SV2527, 1015 Lausanne (Svizzera)

Dr. med . Michele De Palma

CHF 138’000.00.


Dissecting the role of autophagy in normal and malignant B cells towards a rational novel therapeutic target in malignant B cell lymphomas 

Inselspital, Universitätsklinik für Medizinische Onkologie, 3010 Bern (Svizzera)

Dr. Urban Nowak

CHF 70’000.00.


A single-arm, phase II trial evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsiv breast cancer who desire pregnancy. Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer (POSITIVE)

University of Bern, Departement of Medical Oncology, Murtenstrasse 35,

3010 Bern (Svizzera)

Dr.ssa Manuela Rabaglio  

CHF 216'000.00.


Innate Lympoid Cells (ILCs). A novel effector cell in human cancer

University of Lausanne, Ludwig Center for Cancer Research, Av. Pierre Decker 4,

1005 Lausanne (Svizzera)

Dr.ssa Camilla Jandus-Marone, 

CHF 169'000.00.


Inhibition of CD27 and BCR/ABL signaling in leukemia stem cells

Institute for Medical Oncology, Inselspital University Hospital 3010 Bern (Svizzera)

Prof.  Dr. med. Adrian Ochsenbein

CHF 110’670.00.


Identification of novel genetic and epigenetic determinants for oncogenic

transformation in patients with systemic mastocytosis

Institute for Research in Biomedicine, Via Vincenzo Vela 6, 6500 Bellinzona


Silvia Monticelli, PhD

CHF 129’740.00.


Identification of novel targets in central nervous systeminfiltration in acute T lymphoblastic leukaemia

Institutefor Research in Biomedicine (IRB), 6500 Bellinzona (Svizzera)

Fabio Grassi MD PhD



The role of MYC in cancer cell invasion and metastasis

Centrepluridisciplinaire d'Oncologie, Rue du Bugnon 46, 1011 Lausanne (Svizzera)

Anita Wolfer MD PhD

CHF 150'000.00.


Mechanism of small cell lung cancer

Divisionof Experimental Oncology, CePO, CHUV and University of Lausanne, Chemin deBoveresses 155, 1066 Epalinges(Svizzera)

Tatiana Petrova PhD



Exploring the role of Toll-interacting protein in colitis-associatedcolorectal cancer development 

CHUV,BH10-535, Rue du Bugnon 46, 1011 Lausanne (Svizzera)

Dr. Michel Maillard



Therole of calretinin in asbestos-induced malignant mesothelioma investigated inthe NF2+/- mouse model 

Unitof Anatomy, Dept. Of Medicine, University of Fribourg, Route AlbertGockel 1 1700 Fribourg (Svizzera)

Prof. Beat Schwaller



Functional characterization of an 11q24.3 gain contributing to the pathogenesis of diffuse large B cell lymphoma by blocking B-cell maturation Istituto Oncologico di Ricerca, Via Vela 6, 6500 Bellinzona (Svizzera)

Prof.  Dr. med. Francesco Bertoni 

CHF 231’000.00.


The role of chemokine synergy-inducing molecules in controlling the tumor microenvironment, cell migration and metastasis

Institute for Research in Biomedicine, Via Vela 6, 6500 Bellinzona (Svizzera)

Dr.ssa Mariagrazia Uguccioni

CHF 173’000.00.


PI3K isoforms in Melanoma Formation and Progression

Institute Biochemistry & Genetics, Departement of Biomedicine, Mattenstrasse 28, Basilea, (Svizzera).

PhD Romina Marone

CHF 45'200.00


Functional characterization of endoplasmic reticulum-associated protein degradation regulators implicated in tumor progression.

IRB, Istituto di Ricerca in Biomedicina, Bellinzona, (Svizzera).

PhD Maurizio Molinari

CHF 190'000.00 


Analisi delle proteine che interagiscono col recettore CXCR4 in diversi tessuti. Progetto CXCR4, richiesta di estensione.

IRB, Istituto di Ricerca in Biomedicina, Bellinzona, (Svizzera). 

PhD Tiziana Apuzzo

CHF 40'000.00


Exploring tumor-specific genes as potential novel drug targets in colon cancer.

IOSI, Istituto Oncologico della Svizzera Italiana, Bellinzona, (Svizzera).

Dr. med. Pascale Anderle

CHF 59’000.00


Translational research workshop on gastroinstestinal tumors 

ESMO (European Society for Medical Oncology), Lugano-Viganello,(Svizzera).

CHF 50’000.00


Ottimizzazione delle terapie endocrine per un trattamento individualizzato del cancro al seno: identificazione di nuovi parametri in seno allo studio TEXT del IBCSG, International Breast Cancer Study Group.

IOSI, Istituto Oncologico della Svizzera Italiana, Lugano-Viganello, (Svizzera).

Dr. med. Olivia Pagani

CHF 280'000.00


Identification of prognostic abnormalities in B-cell chronic lymphocytic leukaemia.

IOSI, Istituto Oncologico della Svizzera Italiana, Bellinzona, (Svizzera).  

Dr. med. Francesco Bertoni 

CHF  342’000.00


Kinase (P13K) in cancer-role for lipid compartmentalizazion.

Institute Biochemistry & Genetics

Departement of Biomedicine, Phosphoinositide 3, Basilea, (Svizzera).        

Prof. Matthias P. Wymann PhD

CHF 40’000.00


Squamous cell anal cancer, chemoradiation, resistance predicitive molecular markers, immunohistochemistry, florescent in situ hybridizazion genemutations.

Istituto Cantonale di Patologia, Locarno, (Svizzera).   

Dr. med. Milo Frattini

CHF 110'000.00


Analisi delle proteine che interagiscono col recettore CXCR4 in diversi tessuti.

IRB, Istituto di Ricerca in Biomedicina, Bellinzona, (Svizzera).

PhD Tiziana Apuzzo

CHF 36'776.00


British Columbia Cancer Agency, Vancouver, (Canada).

Dr. med. Alden Moccia

CHF 124'000.00


Piattaforma comunicativa sul sistema del cancro allestita dalla Fondazione Oncologia Lago Maggiore, Locarno, (Svizzera) in collaborazione con l’Institute of Communication and Health dell’USI, Università della Svizzera Italiana, Lugano, (Svizzera).

Dr. med. Augusto Pedrazzini

CHF 223'900.00


Cell super-competition and the discovery of novel markers and targets for detection and/or treatment of early stages of cancer.

Istituto Cantonale di Patologia, Locarno, (Svizzera).

MD PhD Davide Soldini

CHF 29'600.00


Apertura di una Unità di microdissezione laser.

IOSI, Istituto Oncologico della Svizzera Italiana, Bellinzona, (Svizzera).

Dr. med. Carlo Catapano

Dr. med. Pascale Anderle Pedone

CHF 295'000.00


Premio 2005 Fondazione San Salvatore, per ricercatori esordienti.

Dr. med. Mifiana Urosevic, Zurigo, (Svizzera).

CHF 30'000.00


B2-adrenergic receptor influence in dendritic cell-based cancer vaccines. 

Istituto Cantonale di Patologia, Locarno, (Svizzera).

Dr. med. Georges Jean-Marie Maestroni 

CHF 106'900.00


Cellular function of HsPi of HsPI 3-Kinase-C2a assessment of its role in transcription, centrsome integrity and cell cycle regulation.

IRB, Istituto di Ricerca in Biomedicina, Bellinzona, (Svizzera).

Prof. Marcus Thelen

CHF 176’958.00


Molecular and biological mechanisms of non-Hodgkin’s lymphoma growth at extranodal sites.

IRB, Istituto di Ricerca in Biomedicina, Bellinzona, (Svizzera).

Dr. med. Mariagrazia Uguccioni

CHF 127’420.00


Studi di citogenetica avvalendosi della tecnica di FISH.

Istituto Cantonale di Patologia, Locarno, (Svizzera).

PhD Dr. med . Luca Mazzucchelli

CHF 108'000.00


Role of Akt/PKB and pericytes in protecting endothelial cells against tumor Necrosis Factor-induced apoptosis.

Centre Pluridisciplinaire d’Oncologie, Faculté de Médicine, Université de Lausanne, Epalinges, (Svizzera).

Dr. med. Curzio Rüegg

CHF 137’252.00


Premio 2002 Fondazione San Salvatore, per ricercatori esordienti.

Departement of Experimental Haematology, Queen Mary’s Scool of Medicine and Dentistry, London e

IOSI, Istituto Oncologico della Svizzera Italiana, Bellinzona, (Svizzera).

Dr. med. Francesco Bertoni

CHF 30’000.00


Hospice Ticino, Lugano, (Svizzera).

Sviluppo e presenza medica nell’ area del Sopraceneri

CHF 102’000.00


Molecular characterization of chromosome 11q in primary extranodal diffuse large B-celle lymphomas.

IOSI, Istituto Oncologico della Svizzera Italiana, Bellinzona, (Svizzera).

Dr. med. Francesco Bertoni

CHF 180'000.00


“Pilot study: Breast cancer data base (Carma)”.

IOSI, Istituto Oncologico della Svizzera Italiana, Bellinzona, (Svizzera).

Prof. Dr. med. Aron Goldhirsch,

Dr. med. Olivia Pagani, 

Dr. med. Rossella Graffeo, 

Prof. Dr. med. Jacques Bernier

CHF 130'000.00


Ricerca nel campo dell’immunologia oncologica allo Sloan Kettering

Cancer Center, New York, (USA).

Dr. med. Camilla Marone

CHF 10'000.00


Premio 2001 Fondazione San Salvatore, per ricercatori esordienti.

Anatomisches Institut der  Universität, Berna, (Svizzera).

Dr. med. Valentin Djonov

CHF 30'000.00


Premio 2000 Fondazione San Salvatore, per ricercatori esordienti.

Dr. med.  A.F. Ochsenbein, 

Institut für Medizinische Onkologie Inselspital, Berna, (Svizzera).

CHF 20'000.00

PhD Dr. med.  Luca Mazzucchelli, 

Pathologisches Institut, Berna, (Svizzera).

CHF 20'000.00


Chemokine axpression and functions in Hodgkin’s disease.

Pathologisches Institut, Universität Bern, Berna (Svizzera).

PhD Dr. med.  Luca Mazzucchelli

CHF 100’000.00


Analsys of the immunoglobulin heavy chain variable region in nodal marginal zone B-cell lymphoma and lymphoplasmacytoid lymphoma.

IOSI, Istituto Oncologico della Svizzera Italiana, Bellinzona, (Svizzera).

Dr. med. Emanuele Zucca

CHF 25’000.00


Neural influence on dendritic cell generation and function.

Istituto Cantonale di Patologia, Locarno, (Svizzera).

Dr. med. Georges Jean-Marie Maestroni

CHF 25’000.00


Registro di donatori non apparentati di midollo.

Servizio Trasfusioni della Svizzera Italiana, Lugano, (Svizzera).

Dr. med. Damiano Castelli

CHF 80'000.00


Premio 1999 Fondazione San Salvatore per ricercatori esordienti.

Dr. med. Uwe Zangemeister-Wittke

Abt. für Onkologie, Universitätspital Zürich, Zurigo (Svizzera).

CHF 30'000.00

Effect of iNOS Expression on PhlP (a colon carcinogen) induced apoptosis and mutagenicity

Institut de Pharmacologie et Toxicologie, Losanna (Svizzera).

Dr. med. Phaik Morgenthaler Leong

CHF 60'000.00


Evaluating extranodal stage I and II low-grade lymphomas of the PMH.

Princess Margaret Hospital,

Department of Radiation Oncology, University of Toronto, (Canada).

Dr. med. Thomas Lippuner

CHF 30'000.00

Messa a punto dell’analisi BRCA1 e BRCA2 in Ticino.

Laboratorio Bioanalitico SA, Savosa, (Svizzera).

Dr. med. Alberto Pedrazzini

Dr. med. Gianbattista Soldati

CHF 60'000.00

The mitogenic action of phosphoinositide 3-kinases.

Istituto di Biochimica dell’Università di Friburgo, (Svizzera).

Dr. med. Matthias Paul Wymann

CHF 40'000.00


Transfert du gene Ku 32 pour augmenter la radiosensibilité de cellules de hamster et des cellules tumorales humains.

Ospedale San Giovanni, Bellinzona, (Svizzera).

PhD Dr. med, J. Bernier, 

Dr. med. J. Bourhis, 

Dr. med. Ch. Badie,

CHF 72’233.00

Investigation of the clinical relevance of a novel subunit of the 26S proteasome which confers resistance to antitumour drugs in vistro and is variably expressed in tumour cell lines.

Servizio Oncologico cantonale, Bellinzona, (Svizzera).

Dr. med. Vito Spataro

CHF 24’000.00

Pathological role of cathepsin B in osteoarhriris splicing of mRNA.

Zentrum für Experimentelle Rheumatologie,

Universität Zürich, Zurigo (Svizzera).

Prof. Dr. med. Antonio Baici

CHF 89'000.00

Premio 1998 Fondazione San Salvatore per ricercatori esordienti.

Dermatologische Klinik Universitätsspital Zürich, Zurigo (Svizzera).

Dr. med. Reihnard Georg Dummer

CHF 30’000.00           


Registro Svizzero dei Donatori di Midollo, Berna, (Svizzera).

CHF 50'000.00


Phage display libraries for the identification of cell-targeting peptides for growth and activation receptors.

Brigham and Women’s Hospital, Department of Pathology, Boston, (USA).

PhD Dr. med . Luca Mazzucchelli

CHF 45'000.00


Characterization and distribution of alpha-1 adrenoceptors in human hematopoietic cells: a basis for new therapeutic strategies in oncology?.        

Istituto Cantonale di Patologia, Locarno, (Svizzera).

Dr. med. Georges Jean -Marie Maestroni

CHF 100'000.00


Study of sterol-regulated proteolytic processing of sterol regulatory element binding protein (SREBP) in vivo.

Southwestern Medical Center, Department molecular Genetic, University of Texas, Dallas, (USA).

Dr. med. Luca Barella

CHF 25’000.00


Gastric MALT lymphoma as a model of tumour progression: evolution from Helicobacter pylori gastritis to low-grade and high-grade lymphomas.

Servizio Oncologico Cantonale, Bellinzona, (Svizzera).

Dr. med. Emanuele Zucca

CHF 150’000.00


Registro Svizzero dei Donatori di Midollo, Berna, (Svizzera).

CHF 50'000.00


Angiogenesi, neovascolarizzazione del tumore. Identificazione dell’ inibitore per arrestare la crescita in vivo.

Laboratory of tumor Biology and Genetics, Neurosurgery Service, CHUV, Losanna, (Svizzera).

Dr. med. Erwin G. Van Meir

CHF 82'000.00


Analyse du récepteur pour l’antigène des lymphocytes en cas de maladie  greffon contre l’hôte après allogreffe osseuse HLA compatible : une étape vers la caractérisation des antigènes mineurs d’ histocompatibilité. Ospedale Cantonale di Ginevra, Ginevra, (Svizzera).

Dr. med. Pierre Yves Dietrich

CHF 136'260.00


Corso di perfezionamento di terapia radiante in Francia.

Clinica di radioterapia Gustave-Roussy, Villejuif, (Francia).

Dr. med.  Susanne Diener

CHF 40'000.00


Interphase cytogenetic Analysis by  fluorescent  non radioactive in-situ

Hybridization (metodo FISCH) in the diagnosis and study of centrocytic lymphoma.

Ospedale San Giovanni Fondo Oncologico Ticinese ”OSG” Trapianti, Bellinzona, (Svizzera).

CHF 50'000.00


Corso di perfezionamento in cure palliative a Edmonton,(Canada).

Dr. med. Hans Neuenschwander

CHF 30'000.00


Soggiorno di due anni presso il “New York Blood Center” New York ed il “Departement of Laboratory Medicine” della Georgetown University Medical Center a Washington (USA)  

Dr. med. Beat M. Frey

CHF 100'000.00


Esperimenti con cellule modificate geneticamente, per la produzione di varie citochine presso il laboratorio del Prof. Dr. J.A. Norton, St. Louis, (USA)


Dr. med. A. Oertli

CHF 40'000.00


Niveau d’information à propos de la maladie et du traitement, dépréssion et anxiété chez les patients cancéreux,

Université de Genève, Ginevra (Svizzera).

Dr. med. Marc Archinard    

Dr. med. André Haynal

CHF 152'309.00


Istituto di Patologia di Locarno (Svizzera).

Dr. med. Ennio Pedrinis

CHF 20'286.00


ATP-Assay, Adenosintriphosphat. Test sulla sensibilità di tumori ginecologici e mammari alle applicazioni chemoterapeutiche.

Universitätsfrauenklinik Zürich, Zurigo (Svizzera).

Prof. Dr. med. Urs Haller  

Dr. med. Ossi R. Koechli

CHF 143’646.00

Gruppo di Lavoro Interdisciplinare ”Senologia Cliniche Luganesi”, Lugano (Svizzera).

Dr. med. Marco Varini

CHF 50'000.00   


In vitro assay of intrinsic radioresistance as predictive test of radiocurability

Ospedale San Giovanni, Bellinzona (Svizzera)

Ospedale Civico, Lugano (Svizzera)

Ospedale Beata Vergine, Mendrisio (Svizzera)

Ospedale La Carità, Locarno (Svizzera)

Centre Hospitalier Universitaire Vaudois, Losanna (Svizzera)

CHF 465’000.00       


Krebsatlas der Schweiz (Zürich/Basel).

Schweizerische Krebsliga, Berna, (Svizzera).

Dr. med. G. Schüler 

Dr. med. M. Bopp   

CHF 10’000.00


Tumor Infiltrating Lymphocytes.

Adt Forschung des Dept.Chirurgie,

Universität, Basilea, (Svizzera).

PhD Dr. med. Michael Heberer

CHF 260’000.00


The Role of pineal gland immunity.

Istituto Cantonale di Patologia, Locarno, (Svizzera).

Dr. med. Georges Jean-Marie Maestroni 

Dr. med. Ario Conti

CHF 20'000.00

Evolution Psychologique des patients cancéreux.

Unité de medicine psychosomatique et psychosociale,

Université de Genève, Ginevra (Svizzera).

Dr. med. Marc Archinard 

Prof. Dr. med. André Haynal    

CHF 140'000.00


Ricostituzione immunologica dopo chemioterapia.

Ospedale La Carità, Servizio Oncologico, Locarno, (Svizzera).

Dr. med. Augusto Pedrazzini 

CHF 100'000.00


Schweizerische Krebsliga

Kisk Kommission der Krebsliga über Iionisierende Strahlen und Krebs, Berna, (Svizzera).

CHF. 100’000.00